British Association of Surgical Oncology Guidelines. The management of metastatic bone disease in the United Kingdom

European Journal of Surgical Oncology

Volumn 25, Issue 1, 1999, Pages 3-23

  Bishop, H M ^a   Cameron, D A ^a   Coleman, R ^a   Davies, A M ^a   Dewar, J A ^a   Evans, A ^a   Harnett, A N ^a   McCloskey, E ^a   O'Donoghue, D ^a   Pullicino, V ^a   Robertson, J ^a   Tillman, R M ^a   Van Schaick, S H ^a   Blamey, R W ^a  

^a Brit Assoc Oral Maxillofacial Surg   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; ANTIULCER AGENT; CLODRONIC ACID; HORMONE; OPIATE; PAMIDRONIC ACID; SAMARIUM; STEROID; STRONTIUM;

ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; HUMAN; HYPERCALCEMIA; INTRAVENOUS DRUG ADMINISTRATION; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PAIN; PALLIATIVE THERAPY; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; SPINAL CORD COMPRESSION;

EID: 0033082132     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1053/ejso.1998.0593     Document Type: Article

References (62)

1. Campbell F.C., Blamey R.W., Elston C.W., Morris A.H., Nicholson R.I., Griffiths K., Haybittle J.L. Quantitative oestradiol receptor values in primary breast cancer and response of metastases to endocrine therapy. Lancet. ii: 1981; 1317-1319.
2. Coleman R.E., Rubens R.D. The clinical course of bone metastases from breast cancer. Br J Cancer. 56: 1987; 61-66.
3. O'Donoghue D.S., Howell A., Walls J. Orthopaedic management of structurally significant bone disease in breast cancer metastases. J Bone Joint Surg (Br). 79:1997; 98.
4. Department of Health, Improving Outcomes in Breast Cancer - The Research Evidence; Improving Outcomes in Breast Cancer - The Manual.
5. US Department of Health and Human Services, Agency for Health Care Policy and Research.Acute Pain Management: Operative or Medical Procedures and Trauma.
6. GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients: a multicentre randomised controlled trial. JAMA. 271: 1994; 1587-1592.
7. Roselli del Turco M., Palli D., Cariddi A., Ciatto S., Pancini P., Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomised trial. National Research Council Project on Breast Cancer Follow-up. JAMA. 271: 1994; 1593-1597.
8. Bishop H.M., Blamey R.W., Morris A.H., Rose D.H., Preston B., Lane Joyce, Doyle P.J. Bone scanning; lack of value in the follow-up of patients with breast cancer. Br J Surg. 66: 1979; 752-754.
9. Molina R., Gion M. Use of blood tumour markers in the detection of recurrent breast cancer. Breast. 7: 1998; 187-189.
10. Jager W., Kramer S., Lang N. Disseminated breast cancer: does early treatment prolong survival without symptoms? Breast. 4: 1995; 62-63.
11. Nicolini A., Anselmi L., Michelassi C., Carpi A. Prolonged survival by 'early' salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer. 76: 1997; 1106-1111.
12. Crippa F., Bombardieri E., Seregni E., Castellani M.R., Gasparini M., Maffioli L., Pizzichetta M., Buraggi G.L. Single determination of CA15-3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med. 36: 1992; 52-55.
13. Sim F.H., Frassica F.J., Chao EYC. Orthopaedic management using new devices and prostheses. Clin Orthop Rel Res. 312: 1995; 160-172.
14. Fidler M.W. Incidence of fracture through metastases in long bones. Acta Orthop Scand. 52: 1981; 623-627.
15. DeWald R.L., Bridwell K.H., Prodromas C., Roots M.F. Reconstructive surgery as palliation for metastatic malignancy of spine. Spine. 10: 1985; 21.
16. Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fracture. Clin Orthop Rel Res. 249: 1989; 256.
17. Harrington K.D. Orthopaedic management of extremity and pelvic lesions. Clin Orthop Rel Res. 312: 1995; 136-147.
18. ICRU 50. Prescribing and Reporting Photon Beam Therapy.
19. Resche I., Chatal J-F, Pecking A., Ell P., Duchesne G., Rubens R., Fogelman I., Houston S., Fauser A., Fischer M., Wilkins D. A dose-controlled study of 153Sm-ethylenediaminetetra- methylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 33: 1997; 1583-1591.
20. Townsend P.W., Rosenthal H.G., Smalley S.R., Cozad S.C., Hassanien R.E. Impact of postoperative radiation therapy and other perioperative factors on outcome after orthopaedic stabilisation of impending or pathologic fractures due to metastatic disease. J Clin Oncol. 12: 1994; 2345-2350.
21. Posner J.B. Back pain and epidural spinal cord compression. Med Clin North Am. 71: 1987; 185-205.
22. Cobb C.A., Leavens M.E., Eckles N. Indications for nonoperative treatment of spinal cord compression due to breast cancer. J Neurosurg. 47: 1977; 653-658.
23. Siegal T. Current considerations in the management of neoplastic spinal cord compression. Spine. 14: 1989; 223-238.
24. Jensen E.V. Hormone dependency of human breast cancer (Editorial). Cancer. 46:1980; 2759-2761.
25. Ling P.J., A'Hern R.P., Hardy J.R. Analysis of survival following treatment of tumour-induced hypercalcaemia with intravenous pamidronate (APD). Br J Cancer. 72: 1995; 206-209.
26. O'Rourke N.P., McCloskey E.V., Kanis J.A. Tumour-induced hypercalcaemia: a case for active treatment. Clin Oncol R Coll Radiol. 6: 1994; 172-176.
27. Purohit O.P., Radstone C.R., Anthony C., Kanis J.A., Coleman R. A randomised double-blind comparison of intravenous pamidronate and clodronate in the hypercalcaemia of malignancy. Br J Cancer. 72: 1995; 1289-1293.
28. Body J.J., Dunon J.C. Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type. Ann Oncol. 5: 1994; 359-363.
29. O'Rourke N.P., McCloskey E.V., Vasikaran S., Eyres K., Fern D., Kanis J.A. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer. 67: 1993; 560-563.
30. Urwin G.H., Yates A.J., Gray R.E., Hamdy N.A., McCloskey E.V., Preston F.E., Greaves M., Neil F.E., Kanis J.A. Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone. 8:1987; S43-51.
31. Glover D., Lipton A., Keller A., Miller A.A., Browning S., Fram R.J., George S., Zelenakas K., Macerata R.S., Seaman J.J. Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study. Cancer. 74: 1994; 2949-2955.
32. Purohit O.P., Anthony C., Radstine C.R., Owen J., Coleman R.E. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer. 70: 1994; 1289-1293.
33. Neri B., Gemelli M.T., Sambataro S., Colombi L., Benvenuti F., Ludovici M., Pacini P. Subjective and metabolic effects of clodronate in patients with advanced breast cancer and symptomatic bone metastases. Anticancer Drugs. 3: 1992; 87-90.
34. Ernst D.S., MacDonald R.N., Paterson A.H., Jensen J., Brasher B., Bruera E. A double-blind, cross-over trial of intravenous clodronate in metastatic bone pain. J Pain Symptom Management. 7: 1992; 4-11.
35. Vinholes J., Purohit O., Abbey M., Eastell R., Coleman R.E. Relationship between biochemical and symptomatic response in a double-blind trial of pamidronate for metastatic bone disease. Ann Oncol. 8: 1997; 1243-1250.
36. Hortobagyi G.N., Theriault R.L., Porter L. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med. 335: 1996; 1785-1789.
37. Conte P.F., Giannessi P.G., Latreille J., Mauriac L., Koliren L., Calabresi F., Ford J.M. Delayed progression of bone metastases with pamidronate in breast cancer patients: a randomised, multicenter phase III trial. Ann Oncol. 5:1994; S41-4.
38. Paterson A.H., Powles T.J., Kanis J.A., McCloskey E., Hanson J., Ashley S. Double-blind controlled trial of clodronate in patients with bone metastases from breast cancer. J Clin Oncol. 11: 1993; 59-65.
39. Bierman W.A., Cantor R.I., Fellin F.M., Jakobowski J., Hopkins L., Newbold RC III. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone. Bone. 12:1991; S37-42.
40. Body J.J., Dumon J.C., Gineyts E., Delmas P.D. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. Br J Cancer. 75: 1997; 408-412.
41. Saarto T., Blomqvist C., Valimaki M., Makela P., Sarna S., Elomaa I. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens. Br J Cancer. 75: 1997; 602-605.
42. Powles T.J., McCloskey E., Paterson A.H., Ashley S., Tidy V.A., Nevantaus A., Rosenqvist K., Kanis J. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 90: 1998; 704-708.
43. Theriault R.L., Sellin R.V. Estrogen-replacement therapy in younger women with breast cancer. J Natl Cancer Inst Monogr. 16: 1994; 149-152.
44. Roy J.A., Sawka C.A., Pritchard K.I. Hormone replacement therapy in women with breast cancer. Do the risks outweigh the benefits? J Clin Oncol. 14: 1996; 997-1006.
45. Sasaki A., Boyce B.F., Story B., Wright K.R., Chapman M., Boyce R., Mundy G.R., Yoneda T. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res. 55: 1995; 3551-3557.
46. Kanis J.A., Powles T., Paterson A.H.G., McCloskey E.V., Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 19: 1996; 663-667.
47. Diel T.J., Solomeyer E.F., Costa S.D. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 339: 1998; 357-363.
48. Coleman R.E., Fogelman I., Rubens R.D. Bone scan flare predicts successful therapy for bone metastases. J Nucl Med. 29: 1988; 1354-1359.
49. Hayward J.L., Carbone P.P., Heuson J.C., Kumaoka S., Segaloff A., Rubens R.D. Assessment of response to therapy in advanced breast cancer. Cancer. 39: 1977; 1289-1293.
50. Brown A.L., Middleton G., MacVicar A.D., Husband JES. TI weighted magnetic resonance imaging in breast cancer vertebral metastases: changes on treatment and correlation with response to therapy. Clin Radiol. 53: 1998; 493-501.
51. American Society of Clinical Oncology. Clinical practice guidelines for the use of tumour markers in breast and colorectal cancer. J Clin Oncol. 14: 1996; 2843-2877.
52. Robertson J.F.R., Pearson D., Price M.R., Selby C., Blamey R.W., Howell A. Objective measurement of therapeutic response in breast cancer using serum markers. Br J Cancer. 64: 1991; 757-763.
53. Robertson J.F.R., Jaeger W., Syzmendera J.J. The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markers. Eur J Cancer. 1999;(in press).
54. Dixon A.R., Jackson L., Chan S.Y., Badley R.A., Blamey R.W. Continuous chemotherapy in responsive metastatic breast cancer. A role for tumour markers? Br J Cancer. 68: 1993; 181-185.
55. World Health Organisation, Cancer Pain Relief: With a Guide to Opioid Availability.
56. O'Neill B., Fallon M. ABC of palliative care: principles of palliative care and pain control. Br Med J. 315: 1997; 801-804.
57. Zech, Grond S., Lynch J. Validation of World Health Organisation guidelines for cancer pain relief: a 10 year prospective study. Pain. 63: 1995; 65-76.
58. Fallon M. Opioid rotation: does it have a role? Palliative Med. 11: 1997; 177-178.
59. Sykes J., Johnson R., Hanks G.W. ABC of palliative care: difficult pain problems. Br Med J. 315: 1997; 867-869.
60. Onghena P., Van Houdenhove B. Antidepressant-induced analgesia in chronic non-malignant pain: a meta-analysis of 39 placebo controlled studies. Pain. 49: 1992; 205-219.
61. McQuay H., Carrol D., Jadad A.R. Anticonvulsant drugs for management of pain: a systematic review. Br Med J. 311: 1995; 1047-1052.
62. World Health Organization, WHO Handbook for Reporting Results of Cancer Treatment. Geneva: 1979.